Akèy › Limfòm Non-Hodgkin › Minnesota
Etid klinik pou Limfòm Non-Hodgkin nan Minnesota
19 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
Tèks ofisyèl etid la (Anglè)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Mayo Clinic in Rochester, Minnesota, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06090539Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Minnesota, Minneapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT03666000A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Research Site, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07123454Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- University of Minnesota/Masonic Cancer Center, Minneapolis
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Mayo Clinic, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Minnesota Oncology - Burnsville, Burnsville
- ak 31 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Mayo Clinic- Minnesota, Rochester
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Mayo Clinic- Minnesota, Rochester
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06876649Auto Stem Cell Transplant for Lymphoma Patients
- Masonic Cancer Center, University of Minnesota, Minneapolis
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Nov 4, 2025 · NCT03125642SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Oct 14, 2025 · NCT00626496IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- University of Minnesota, Minneapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2025 · NCT06119685Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.